0001209191-23-035126.txt : 20230607
0001209191-23-035126.hdr.sgml : 20230607
20230607165031
ACCESSION NUMBER: 0001209191-23-035126
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230605
FILED AS OF DATE: 20230607
DATE AS OF CHANGE: 20230607
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Turner Christopher Durant
CENTRAL INDEX KEY: 0001862146
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40671
FILM NUMBER: 23999601
MAIL ADDRESS:
STREET 1: ONE BROADWAY, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nuvalent, Inc.
CENTRAL INDEX KEY: 0001861560
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE BROADWAY, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 508-446-2272
MAIL ADDRESS:
STREET 1: ONE BROADWAY, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-05
0
0001861560
Nuvalent, Inc.
NUVL
0001862146
Turner Christopher Durant
C/O NUVALENT, INC.
ONE BROADWAY, 14TH FLOOR
CAMBRIDGE
MA
02142
0
1
0
0
Chief Medical Officer
1
Class A Common Stock
2023-06-05
4
M
0
10235
6.89
A
24748
D
Class A Common Stock
2023-06-05
4
S
0
10235
44.86
D
14513
D
Stock Option (Right to Buy)
6.89
2023-06-05
4
M
0
10235
0.00
D
2031-04-29
Class A Common Stock
10235
316430
D
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 21, 2021.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.80 to $45.02, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price.
The shares underlying this option vest as follows: 25% of the shares vested on March 22, 2022, and the remainder have vested or shall vest over the next three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
/s/ Deborah Ann Miller, attorney-in-fact
2023-06-07